Sign inJoin waitlistJoin the waitlist

Joaquim Bellmunt

Director, Bladder Cancer Center · Mass General Brigham

Credentials: · · ·

History

Bladder Cancer Center · Mass General Brigham
Present
Mass General Brigham
Present

Vall d'Hebron Hospital
1985–1987
Vall d'Hebron Hospital
1982–1985
Facultat de Medicina
1978–1982

Research

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm,…
The Lancet · 2016 · 2,972 citations
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
New England Journal of Medicine · 2017 · First of 21 authors · 2,802 citations
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
European Urology · 2017 · 2,361 citations

Toni Choueiri
90 papers
JR
Jonathan Rosenberg
71 papers
Cora Sternberg
58 papers
GS
Guru Sonpavde
56 papers
Matthew Galsky
50 papers
Petros Grivas
44 papers
Daniel Petrylak
33 papers
LH
Lauren Harshman
30 papers
Neeraj Agarwal
28 papers
Evan Yu
27 papers
DB
Dean Bajorin
26 papers
Sumanta Pal
26 papers

Clinical trials

Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
Principal investigator · Recruiting
Dana-Farber Cancer Institute
2024–2028
Avelumab Plus Carboplatin-gemcitabine in Urothelial Carcinoma
Principal investigator · Completed · Phase 2
Associació per a la Recerca Oncologica, Spain
2018–2022
Paclitaxel and TAK-228 in Urothelial Carcinoma
Principal investigator · Unknown · Phase 2
Associació per a la Recerca Oncologica, Spain
2018–2020
Pazopanib in Second-line Therapy in Renal Cell Carcinoma
Study chair · Unknown · Phase 2
Associació per a la Recerca Oncologica, Spain
2012–2015